Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by Armin Schulz on April 5th, 2023 | 12:25 CEST

BioNTech, BioNxt Solutions, Bayer - The big one is only a matter of time

  • Biotechnology
  • Pharma
  • Cancer

The biotech and pharmaceutical industry is currently in a constant state of flux, driven by the introduction of new technologies and the fight against global health problems. Producing medicines and therapies to alleviate diseases is of great value to people's health. Against the backdrop of an ageing population in industrialised nations, the sector will continue to be of great importance. A particular focus is on inventing advanced technologies to fight diseases such as cancer, Alzheimer's and Parkinson's. Today we look at three companies in the biotech and pharma sector.

Read

Commented by Nico Popp on April 4th, 2023 | 17:04 CEST

Race against cancer: BioNTech, Bayer, Defence Therapeutics

  • Biotechnology
  • Cancer

BioNTech first became known to the general public about three years ago. At that time, the pandemic was rampant and the first vaccine plans were making the rounds in the media. Among all the big names, BioNTech was initially one of many options for the public. In the meantime, the Company has become so dominant in Germany that the competition has been left behind. We look at what this means for investors and the pharmaceutical industry.

Read

Commented by Nico Popp on March 27th, 2023 | 09:26 CEST

Cost pressure in the healthcare system - how you benefit: Bayer, BioNxt, BioNTech

  • Biotechnology
  • Pharma

What do you think of the German healthcare system? While doctors regularly grumble about bureaucracy and patients about long waiting times or other inconsistencies, a new divide is opening up between pharmaceutical companies. Research-based pharmaceutical companies favour long patent protection, while generics manufacturers want more lax rules. We explain the system and highlight opportunities for investors.

Read

Commented by Juliane Zielonka on March 23rd, 2023 | 08:02 CET

BioNxt Solutions, Bayer, BioNTech - These pharma stocks offer growth potential

  • Biotechnology
  • research
  • Pharma

The risk of cancer is increasing worldwide for people over the age of 50. The reasons for this are lack of sleep and exercise, pre-existing diseases and poor nutrition. It has now also been scientifically proven that permanent stress is a cause of Parkinson's disease. According to the WHO, disabilities and deaths due to Parkinson's are increasing faster worldwide than for any other neurological disease. Pharmaceutical and biotech companies are doing everything they can to improve the quality of life of those affected. The Canadian biotech company BioNxt is working on a comparative study to improve a therapy patch for treating Parkinson's and make accompanying drug products scalable. Bayer subsidiary Bluerock Therapeutics is using data from the Apple Watch to research Parkinson's symptoms. And CEO Uğur Şahin of BioNTech has closed a billion-dollar deal in cancer therapy.

Read

Commented by Fabian Lorenz on March 16th, 2023 | 11:51 CET

Takeover speculation at Defence Therapeutics! What are BioNTech, Morphosys, and Evotec doing?

  • Biotechnology
  • Takeover

Defence Therapeutics is one of the biotech high flyers of the past months. The share has more than doubled since October. And this could be just the beginning. Operationally, things are going well, a strong partner has been acquired, and experts are speculating about a takeover. And what are the German biotechs doing? At BioNTech, it will be exciting at the end of March, because the Mainz-based company needs new blockbusters. At Morphosys, analysts recently saw further downside potential. Will a new management board bring about a turnaround? Evotec also had little positive to report. However, an AI investment in the hype surrounding ChatGPT is making headlines.

Read

Commented by André Will-Laudien on March 15th, 2023 | 17:38 CET

Bayer, BioNxt, BioNTech - Biotech is on the rise again, bring on the blockbusters!

  • Biotechnology
  • vaccine
  • Covid19

The time of the vaccine producers is over because the willingness to vaccinate is declining worldwide. As a result, the entire biotech sector has entered a strong correction phase since the pandemic mode for COVID-19 ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Complicating matters for companies is the significant increase in interest rates for long-term financing of their pipelines. When refinancing costs rise, this often leads to lower valuations. However, some companies are impressing with their innovations and have recently shown significant outperformance to the market. We evaluate the opportunities of some well-known biotech protagonists!

Read

Commented by André Will-Laudien on March 10th, 2023 | 10:15 CET

Defeat cancer! Defence Therapeutics, BioNTech, Morphosys, Bayer - These biotechs are close

  • Biotechnology
  • Cancer

The listed biotechnology sector has entered a strong correction phase since the COVID-19 pandemic mode ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Compounding the problem for companies is the significant increase in interest rates for long-term financing. The segment relies on revolving investor capital, but the corresponding risk parameters have been adjusted upward, making some refinancings extremely expensive. Costs are rising, which is leading to renewed price markdowns. However, some companies are convincing through their innovative strength and have recently outperformed the market. We take a closer look at the blockbuster stocks.

Read

Commented by Fabian Lorenz on March 9th, 2023 | 10:52 CET

BioNTech, Pfizer, Bayer and BioNxt Solutions on the biotech takeover merry-go-round

  • Biotechnology
  • Pharma

2023 could become the year of takeovers in the pharmaceutical and biotech sectors. This is what the experts at PwC expect. Thus, at the JP Morgan industry conference in San Francisco, not only were takeover candidates discussed but billion-dollar transactions were reported. One reason is the Inflation Reduction Act in the USA. This allows negotiations on drug prices. To prevent sales declines, Big Pharma must invest in new top sellers. And it is already doing so. The latest takeover rumor comes from BioNTech partner Pfizer. At BioNTech, the negative news currently outweighs the positive. Whether Bayer will take action with the boss or be taken over itself is not yet entirely clear. But there are also opportunities for investors in the smallcap sector. Take BioNxt Solutions, for example - the Canadian company with its operational focus in Germany recently secured new patents, and the share price has jumped.

Read

Commented by Stefan Feulner on March 1st, 2023 | 14:01 CET

BioNTech, BioNxt Solutions, Bayer - Turn of the tide

  • Biotechnology
  • Covid19

Just how fundamental biotechnology already is for humanity was demonstrated by the development of the various COVID vaccines, which was extremely rapid by historical standards. Previously unknown companies such as BioNTech, Valneva and CureVac came into the focus of the stock market and were able to multiply within a very short time. Even after the pandemic has ended, research in the biotech sector is running at full speed. This is giving rise to new, innovative growth companies that could follow a similar trajectory in the future.

Read

Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET

Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics

  • Biotechnology
  • Cannabis
  • Cancer

Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.

Read